Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Cureus ; 16(7): e64746, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39156238

ABSTRACT

Chest pain is a common and complex symptom that can arise from various etiologies, ranging from benign musculoskeletal conditions to life-threatening cardiovascular events. It is a hallmark symptom of myocardial infarction, angina, and other ischemic heart diseases, necessitating prompt and thorough evaluation. Ongoing chest pain post-procedures and medication administration presents a diagnostic challenge, as it may be indicative of an exacerbation of underlying conditions. We present the case of a 64-year-old Caucasian male who initially presented with severe and persistent chest pain suggestive of an anterior wall ST-elevation myocardial infarction (STEMI). He had a history of coronary artery disease and had recently undergone cardiac catheterization. Despite prompt administration of nitroglycerin and aspirin, the patient's symptoms persisted, prompting emergent percutaneous coronary intervention (PCI). Subsequent to PCI, ongoing chest discomfort persisted, prompting further investigation, which revealed a concurrent lung mass and nodules on imaging. Additional interventions, including repeated PCI procedures and thoracentesis, were undertaken. Unfortunately, the patient's clinical course rapidly deteriorated, culminating in cardiac arrest and unsuccessful resuscitative efforts. This case highlights the complexities inherent in managing intricate cardiovascular conditions and emphasizes the critical importance of maintaining vigilance for concomitant pathologies.

2.
Biomater Sci ; 10(3): 633-653, 2022 Feb 01.
Article in English | MEDLINE | ID: mdl-34994371

ABSTRACT

The ever-growing threat of new and existing infectious diseases in combination with antimicrobial resistance requires the need for innovative and effective forms of drug delivery. Optimal drug delivery systems for existing and newly developed antimicrobials can enhance drug bioavailability, enable site-specific drug targeting, and overcome current limitations of drug formulations such as short elimination half-lives, poor drug solubility, and undesirable side effects. Nanoemulsions (NE) consist of nanometer-sized droplets stabilized by emulsifiers and are typically more stable and permeable due to their smaller particle sizes and higher surface area compared to conventional emulsions. NE have been identified as a promising means of antimicrobial delivery due to their intrinsic antimicrobial properties, ability to increase drug solubility, stability, bioavailability, organ and cellular targeting potentials, capability of targeting biofilms, and potential to overcome antimicrobial resistance. Herein, we discuss non-drug loaded essential oil-based NE that can confer antimicrobial actions through predominantly physical or biochemical mechanisms without drug payloads. We also describe drug-loaded NE for enhanced antimicrobial efficacy by augmenting the potency of existing antimicrobials. We highlight the versatility of NE to be administered through multiple different routes (oral, parenteral, dermal, transdermal, pulmonary, nasal, ocular, and rectal). We summarize recent advances in the clinical translation of antimicrobial NE and shed light on future development of effective antimicrobial therapy to combat infectious diseases.


Subject(s)
Anti-Infective Agents , Nanoparticles , Oils, Volatile , Anti-Infective Agents/pharmacology , Drug Delivery Systems , Emulsions , Particle Size , Solubility
3.
Neuroradiol J ; 35(4): 512-514, 2022 Aug.
Article in English | MEDLINE | ID: mdl-34550824

ABSTRACT

Asystole or bradycardia is a relatively uncommon side effect seen in patients undergoing endovascular embolization using dimethylsulfoxide based liquid embolic agents. We present a case of a patient who underwent dural arteriovenous fistula embolization and experienced bradycardia during Onyx injection but was stabilized and the procedure was completed successfully.


Subject(s)
Central Nervous System Vascular Malformations , Embolization, Therapeutic , Heart Arrest , Bradycardia , Humans , Middle Aged , Polyvinyls , Treatment Outcome
4.
Blood Adv ; 5(15): 3021-3031, 2021 08 10.
Article in English | MEDLINE | ID: mdl-34357379

ABSTRACT

Monoclonal antibodies (mAbs) are a central component of therapy for hematologic malignancies. Widely used mAb agents in multiple myeloma (MM) include daratumumab and elotuzumab. However, not all patients respond to these agents, and resistance is a significant clinical issue. A recently discovered subset of human natural killer (NK) cells lacking expression of FcεRIγ (g-NK cells) was found to have a multifold increase in antibody-dependent effector functions after CD16 crosslinking. In this study, we tested the capacity of g-NK cells to enhance the efficacy of therapeutic mAbs against MM. In vitro, we found that g-NK cells have strikingly superior anti-myeloma cytotoxicity compared with conventional NK (cNK) cells when combined with daratumumab or elotuzumab (∼sixfold; P < .001). In addition, g-NK cells naturally expressed minimal surface CD38 and SLAMF7, which reduced the incidence of therapeutic fratricide. In tumor-naïve murine models, the persistence of g-NK cells in blood and spleen was >10 times higher than that of cNK cells over 31 days (P < .001). In vivo efficacy studies showed that the combination of daratumumab and g-NK cells led to a >99.9% tumor reduction (by flow cytometry analysis) compared with the combination of daratumumab and cNK cells (P < .001). Moreover, treatment with daratumumab and g-NK cells led to complete elimination of myeloma burden in 5 of 7 mice. Collectively, these results underscore the unique ability of g-NK cells to potentiate the activity of therapeutic mAbs and overcome limitations of current off-the-shelf NK cell therapies without the need for cellular irradiation or genetic engineering.


Subject(s)
Antineoplastic Agents, Immunological , Multiple Myeloma , Animals , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Flow Cytometry , Humans , Killer Cells, Natural , Mice , Multiple Myeloma/drug therapy
5.
Annu Int Conf IEEE Eng Med Biol Soc ; 2016: 774-777, 2016 Aug.
Article in English | MEDLINE | ID: mdl-28268441

ABSTRACT

In neural spike sorting systems, the performance of the spike detector has to be maximized because it affects the performance of all subsequent blocks. Non-linear energy operator (NEO), is a popular spike detector due to its detection accuracy and its hardware friendly architecture. However, it involves a thresholding stage, whose value is usually approximated and is thus not optimal. This approximation deteriorates the performance in real-time systems where signal to noise ratio (SNR) estimation is a challenge, especially at lower SNRs. In this paper, we propose an automatic and robust threshold calculation method using an empirical gradient technique. The method is tested on two different datasets. The results show that our optimized threshold improves the detection accuracy in both high SNR and low SNR signals. Boxplots are presented that provide a statistical analysis of improvements in accuracy, for instance, the 75th percentile was at 98.7% and 93.5% for the optimized NEO threshold and traditional NEO threshold, respectively.


Subject(s)
Signal-To-Noise Ratio , Action Potentials , Algorithms , Empirical Research , Models, Theoretical , Neurons/physiology , Signal Processing, Computer-Assisted
SELECTION OF CITATIONS
SEARCH DETAIL